EBS Emergent BioSolutions Inc.

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

Emergent BioSolutions Inc. (EBS) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 earnings released Feb 26, 2026; full results in Exhibit 99.1
• EBS reporting period covers quarter and fiscal year ended Dec 31, 2025

Item 7.01 · Regulation FD Disclosure

• Earnings call scheduled Feb 26, 2026 to discuss Q4 and full-year 2025 financial results
• Presentation slides (Exhibit 99.2) posted to company website ahead of call — key source for operational metrics and guidance

+1 more insights

Other Emergent BioSolutions Inc. 8-K Filings

8-K Mar 3, 2026

Get deeper insights on Emergent BioSolutions Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.